BlueWillow Biologics

Blue Willow Biologics

Biotechnology, 2311 Green Rd, Ann Arbor, Michigan, 48105, United States, 11-50 Employees

bluewillow.com

  • facebook
  • twitter
  • LinkedIn

phone no Phone Number: 17*********

Who is BLUEWILLOW BIOLOGICS

BlueWillow Biologics® is developing and enabling a new generation of safe and effective nasal vaccines to protect global populations from respiratory infections, sexually transmitted dise...

Read More

map

industries-icon Industry: Biotechnology

SIC SIC Code: 2836 | NAICS Code: 325414 | Show More

checked-icon Does something look wrong? Fix it. | View contact records from BLUEWILLOW BIOLOGICS

BlueWillow Biologics Org Chart and Mapping

Chad Costley

Chief Executive Officer

Employees

Chris Euritt

Human Resources Consultant

Stephen Gracon

VP Regulatory and Quality

Chris Brigolin

Senior Research Associate

Shyamala Ganesan

Senior Director Vaccine R&D

Rone Eisma

Senior Research Associate

Jessie Pannu

Manager of Tech Transfer & Manufacturing/ Qa&Qc Lead/ Scientist

signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding BlueWillow Biologics

Answer: BlueWillow Biologics's headquarters are located at 2311 Green Rd, Ann Arbor, Michigan, 48105, United States

Answer: BlueWillow Biologics's phone number is 17*********

Answer: BlueWillow Biologics's official website is https://bluewillow.com

Answer: BlueWillow Biologics's revenue is $25 Million to $50 Million

Answer: BlueWillow Biologics's SIC: 2836

Answer: BlueWillow Biologics's NAICS: 325414

Answer: BlueWillow Biologics has 11-50 employees

Answer: BlueWillow Biologics is in Biotechnology

Answer: BlueWillow Biologics contact info: Phone number: 17********* Website: https://bluewillow.com

Answer: BlueWillow Biologics® is developing and enabling a new generation of safe and effective nasal vaccines to protect global populations from respiratory infections, sexually transmitted diseases, and food allergies. Our novel intranasal NanoVax® adjuvant platform activates mucosal immunity, the body’s first line of defense, while also inducing systemic immunity. We are a clinical-stage company advancing a pipeline of proprietary programs including Peanut Allergy, HSV-2, Covid-19, Anthrax, Pandemic Flu and RSV.

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access